Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.68 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their pipeline. They acknowledged the challenges but are optimistic about upcoming milestones.
Management highlighted ongoing progress in clinical trials.
They expressed confidence in future developments despite current losses.
Madrigal Pharmaceuticals reported a loss per share of $0.68, which was in line with expectations, but no revenue figures were disclosed. The stock rose by 1.25%, indicating that investors may be responding positively to management's commentary on clinical progress and future potential. The lack of guidance suggests uncertainty about short-term performance, but the overall tone was optimistic.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MICROCHIP TECHNOLOGY
Nov 6, 2017